Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174746 · ClinicalTrials.gov registry record · Phase 2
Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,145
- Enrollment target
NCT00174746: Completed Phase 2 study, sponsored by Sanofi.
NCT00174746 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 1,145 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (761% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00174746, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,145 participants
- Enrollment target
Study Summary
To investigate the efficacy and safety of ciclesonide inhaled into the lungs in a range of doses in a new dry powder inhaler compared to ciclesonide inhaled into the lungs using a metered dose inhaler
Interventions
- DRUG AVE2635A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,145 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00174746 record still lists
NCT00174746 is an interventional study that assigns participants to a tested intervention. Its 1,145 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (761% higher).
The record links to 0 conditions, and to 1 intervention - of which AVE2635A is the first listed.
NCT00174746 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00174746 about?
NCT00174746 is a clinical study titled "Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma". To investigate the efficacy and safety of ciclesonide inhaled into the lungs in a range of doses in a new dry powder inhaler compared to ciclesonide inhaled into the lungs using a metered dose inhaler
What is the current status of trial NCT00174746?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,145 participants. The study started on 2005-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00174746?
The interventions under investigation include: AVE2635A (DRUG).
Who is sponsoring clinical trial NCT00174746?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00174746's enrollment target sits among peer trials
1,145 20th of 2000 higher than 1,981 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia